- Home
- ODD vs ACAD Comparison
ODD vs ACAD Comparison
Compare ODD & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- ACAD
- Stock Information
- Founded
- ODD 2018
- ACAD 1993
- Country
- ODD Israel
- ACAD United States
- Employees
- ODD N/A
- ACAD N/A
- Industry
- ODD
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- ACAD Health Care
- Exchange
- ODD Nasdaq
- ACAD Nasdaq
- Market Cap
- ODD 3.8B
- ACAD 3.5B
- IPO Year
- ODD 2023
- ACAD 2004
- Fundamental
- Price
- ODD $45.80
- ACAD $22.00
- Analyst Decision
- ODD Buy
- ACAD Buy
- Analyst Count
- ODD 11
- ACAD 21
- Target Price
- ODD $75.36
- ACAD $29.43
- AVG Volume (30 Days)
- ODD 651.0K
- ACAD 2.0M
- Earning Date
- ODD 11-19-2025
- ACAD 11-05-2025
- Dividend Yield
- ODD N/A
- ACAD N/A
- EPS Growth
- ODD 25.95
- ACAD 615.00
- EPS
- ODD 1.80
- ACAD 1.33
- Revenue
- ODD $751,854,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- ODD $25.43
- ACAD $14.01
- Revenue Next Year
- ODD $20.18
- ACAD $12.00
- P/E Ratio
- ODD $25.47
- ACAD $16.61
- Revenue Growth
- ODD 26.12
- ACAD 14.41
- 52 Week Low
- ODD $35.30
- ACAD $13.40
- 52 Week High
- ODD $79.18
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- ODD 23.41
- ACAD 51.82
- Support Level
- ODD $49.17
- ACAD $20.33
- Resistance Level
- ODD $52.00
- ACAD $22.10
- Average True Range (ATR)
- ODD 2.33
- ACAD 0.81
- MACD
- ODD -0.57
- ACAD 0.23
- Stochastic Oscillator
- ODD 1.11
- ACAD 92.40
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.